- Home
- LUCY vs OGEN Comparison
LUCY vs OGEN Comparison
Compare LUCY & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- OGEN
- Stock Information
- Founded
- LUCY 2017
- OGEN 1996
- Country
- LUCY United States
- OGEN United States
- Employees
- LUCY N/A
- OGEN N/A
- Industry
- LUCY Ophthalmic Goods
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- LUCY Health Care
- OGEN Health Care
- Exchange
- LUCY Nasdaq
- OGEN Nasdaq
- Market Cap
- LUCY 8.9M
- OGEN 2.5M
- IPO Year
- LUCY 2022
- OGEN N/A
- Fundamental
- Price
- LUCY $2.10
- OGEN $1.53
- Analyst Decision
- LUCY
- OGEN
- Analyst Count
- LUCY 0
- OGEN 0
- Target Price
- LUCY N/A
- OGEN N/A
- AVG Volume (30 Days)
- LUCY 5.9M
- OGEN 1.1M
- Earning Date
- LUCY 08-11-2025
- OGEN 08-08-2025
- Dividend Yield
- LUCY N/A
- OGEN N/A
- EPS Growth
- LUCY N/A
- OGEN N/A
- EPS
- LUCY N/A
- OGEN N/A
- Revenue
- LUCY $1,707,470.00
- OGEN N/A
- Revenue This Year
- LUCY $367.48
- OGEN N/A
- Revenue Next Year
- LUCY $166.67
- OGEN N/A
- P/E Ratio
- LUCY N/A
- OGEN N/A
- Revenue Growth
- LUCY 22.75
- OGEN N/A
- 52 Week Low
- LUCY $1.57
- OGEN $1.35
- 52 Week High
- LUCY $11.16
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- LUCY 42.96
- OGEN 27.36
- Support Level
- LUCY $1.95
- OGEN $1.35
- Resistance Level
- LUCY $2.20
- OGEN $4.19
- Average True Range (ATR)
- LUCY 0.34
- OGEN 0.43
- MACD
- LUCY -0.05
- OGEN -0.22
- Stochastic Oscillator
- LUCY 5.12
- OGEN 5.14
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.